Detection of hTERC and c-MYC genes in cervical epithelial exfoliated cells for cervical cancer screening

Li,Tian; Tang,Liangdan; Bian,Duhong; Jia,Ying; Huang,Xin; Zhang,Xinhua

doi:10.3892/ijmm.2014.1699

Detection of hTERC and c-MYC genes in cervical epithelial exfoliated cells for cervical cancer screening

Authors:
- Tian Li
- Liangdan Tang
- Duhong Bian
- Ying Jia
- Xin Huang
- Xinhua Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: March 14, 2014 https://doi.org/10.3892/ijmm.2014.1699
Pages: 1289-1297

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is the principal cause of mortality due to cancer in women worldwide. New predictive markers may increase survival rates by improving the treatment of patients at a high risk for cancer. This study was carried out to investigate the amplification of human telomerase RNA component (hTERC) or/and c-MYC in cervical epithelial exfoliated cells for cervical carcinoma screening. We collected 171 specimens. including speciments from normal cervix, benign lesions, cervical intraepithelial neoplasia (CIN)1, CIN2 and CIN3, or carcinoma in situ, as well as invasive cervical squamous cell carcinoma. Fluorescence in situ hybridization (FISH) was performed to detect alterations in hTERC and c-MYC expression. We analyzed the area under the receiver operating characteristic (ROC) curve (AUC), as well as the sensitivity and specificity of single screening and conjoined screening. There was a trend toward an increasing amplification of 2 genes with the increasing severity of cervical lesions. ROC curve analysis demonstrated that the AUC values of the hTERC gene for the screening of different cervical lesions were >0.8. Compared with the hTERC gene, the AUC of the c-MYC gene for the screening of ≥CIN3 was >0.8 and the AUC for the screening of other cervical lesions was >0.7. For the screening of cervical lesions above the grade of benign lesions, cytological diagnosis was superior to the gene detection with significant differences. For the screening of cervical lesions >CIN1, there were no statistically significant differences (P>0.05) between the hTERC gene and cytological diagnosis, whereas the screening results of c-MYC detection and cytological diagnosis differed significantly (P<0.05). For the screening of cervical lesions >CIN2 or >CIN3, the detection of hTERC and c-MYC genes and cytological diagnosis had similar screening results with no statistically significant differences (P>0.05). In conclusion, using FISH to detect the amplification of hTERC or/and c-MYC on cervical epithelial exfoliated cells may be a useful and specific screening method for precancerous lesions.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Zhang A, Månér S, Betz R, Angström T, Stendahl U, Bergman F, Zetterberg A and Wallin KL: Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer. 101:427–433. 2002. View Article : Google Scholar
3	Wright TC Jr, Massad LS, Dunton CJ, et al: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 11:201–222. 2007. View Article : Google Scholar
4	Christopherson WM, Parker JE, Mendez WM and Lundin FE Jr: Cervix cancer death rates and mass cytologic screening. Cancer. 26:808–811. 1970. View Article : Google Scholar : PubMed/NCBI
5	Quinn M, Babb P, Jones J and Allen E: Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ. 318:904–908. 1999. View Article : Google Scholar : PubMed/NCBI
6	Pak SC, Martens M, Bekkers R, et al: Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol. 47:504–507. 2007. View Article : Google Scholar : PubMed/NCBI
7	Mählck CG, Jonsson H and Lenner P: Pap smear screening and changes in cervical cancer mortality in Sweden. Int J Gynaecol Obstet. 44:267–272. 1994.
8	Liu S, Semenciw R, Probert A and Mao Y: Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer. 11:24–31. 2001. View Article : Google Scholar : PubMed/NCBI
9	Etzioni R, Urban N, Ramsey S, et al: The case for early detection. Nat Rev Cancer. 3:243–252. 2003. View Article : Google Scholar
10	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
11	Cuzick J, Szarewski A, Cubie H, et al: Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 362:1871–1876. 2003. View Article : Google Scholar : PubMed/NCBI
12	Fahey MT, Irwig L and Macaskill P: Meta-analysis of Pap test accuracy. Am J Epidemiol. 141:680–689. 1995.PubMed/NCBI
13	Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W and Paraskevaidis E: Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 104:232–246. 2007. View Article : Google Scholar
14	Mayrand MH, Duarte-Franco E, Rodrigues I, et al: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 357:1579–1588. 2007. View Article : Google Scholar : PubMed/NCBI
15	Nanda K, McCrory DC, Myers ER, et al: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 132:810–819. 2000. View Article : Google Scholar : PubMed/NCBI
16	Guidos BJ and Selvaggi SM: Use of the Thin Prep Pap Test in clinical practice. Diagn Cytopathol. 20:70–73. 1999. View Article : Google Scholar : PubMed/NCBI
17	Zur Hausen H: Papillomaviruses causing cancer: evasion from hostcell control in early events in carcinogenesis. J Natl Cancer Inst. 92:690–698. 2000.PubMed/NCBI
18	Duensing S and Münger K: Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer. 109:157–162. 2004. View Article : Google Scholar : PubMed/NCBI
19	Lazo PA: The molecular genetics of cervical carcinoma. Br J Cancer. 80:2008–2018. 1999. View Article : Google Scholar : PubMed/NCBI
20	Kurtycz D, Nuñez M, Arts T, Bauman C, Harris C, Inhorn S and Meisner L: Use of fluorescent in-situ hybridization to detect aneuploidy in cervical dysplasia. Diagn Cytopathol. 15:46–51. 1996. View Article : Google Scholar : PubMed/NCBI
21	Heselmeyer K, Macville M, Schröck E, Blegen H, Hellström AC, Shah K, Auer G and Ried T: Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer. 19:233–240. 1997. View Article : Google Scholar
22	Thein A, Trková M, Fox M and Parrington J: The application of comparative genomic hybridization to previously karyotyped cervical cancer cell lines. Cancer Genet Cytogenet. 116:59–65. 2000. View Article : Google Scholar
23	Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, Lundsteen C, Bryndorf T, Kryger-Baggesen N, Christensen L, Engelholm SA and Philip J: Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer. 24:144–150. 1999. View Article : Google Scholar
24	Mullokandov MR, Kholodilov NG, Atkin NB, Burk RD, Johnson AB and Klinger HP: Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res. 56:197–205. 1996.
25	Heselmeyer K, Schröck E, du Manoir S, Blegen H, Shah K, Steinbeck R, Auer G and Ried T: Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA. 93:479–484. 1996. View Article : Google Scholar : PubMed/NCBI
26	Kersemaekers AM, van de Vijver MJ, Kenter GG and Fleuren GJ: Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer. 26:346–354. 1999. View Article : Google Scholar : PubMed/NCBI
27	Dellas A, Torhorst J, Jiang F, Proffitt J, Schultheiss E, Holzgreve W, Sauter G, Mihatsch MJ and Moch H: Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genetic hybridization. Cancer Res. 59:3475–3479. 1999.
28	Hidalgo A, Schewe C, Petersen S, Salcedo M, Gariglio P, Schlüns K, Dietel M and Petersen I: Human papilloma virus status and chromosomal imbalances in primary cervical carcinomas and tumor cell lines. Eur J Cancer. 36:542–548. 2000. View Article : Google Scholar : PubMed/NCBI
29	Todd R and Wong DT: Oncogenes. Anticancer Res. 19:4729–4746. 1999.
30	Bishop JM: Molecular themes in oncogenesis. Cell. 64:235–248. 1991. View Article : Google Scholar : PubMed/NCBI
31	Adhikary S and Eilers M: Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 6:635–645. 2005. View Article : Google Scholar : PubMed/NCBI
32	Couturier J, Sastre-Garau X, Schneider-Maunoury S, Labib A and Orth G: Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression. J Virol. 65:4534–4538. 1991.PubMed/NCBI
33	Sastre-Garau X, Favre M, Couturier J and Orth G: Distinct patterns of alteration of myc genes associated with integration of human papillomavirus type 16 or type 45 DNA in two genital tumors. J Gen Virol. 81:1983–1993. 2000.PubMed/NCBI
34	Umayahara K, Hirai Y, Sugiyama Y, et al: Genetic alterations during the progression of early cervical neoplasm. Proc Amer Assoc Cancer Res. 46:57432005.
35	Heselmeyer-Haddad K, Sommerfeld K, White NM, et al: Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol. 166:1229–1238. 2005. View Article : Google Scholar : PubMed/NCBI
36	Sokolova I, Algeciras-Schimnich A, Song M, et al: Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens. J Mol Diagn. 9:604–611. 2007. View Article : Google Scholar
37	Matthews CP, Shera KA and McDougall JK: Genomic changes and HPV type in cervical carcinoma. Proc Soc Exp Biol Med. 223:316–321. 2000. View Article : Google Scholar : PubMed/NCBI
38	Widschwendter A, Ivarsson L, Blassnig A, et al: CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer. 109:163–166. 2004. View Article : Google Scholar : PubMed/NCBI
39	Apostolidou S, Hadwin R, Burnell M, et al: DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer. 125:2995–3002. 2009. View Article : Google Scholar : PubMed/NCBI
40	Rosa MI, Medeiros LR, Bozzetti MC, et al: Accuracy of telomerase in cervical lesions: a systematic review. Int J Gynecol Cancer. 17:1205–1214. 2007. View Article : Google Scholar : PubMed/NCBI
41	Li Y, Ye F, Lü WG, et al: Detection of human telomerase RNA gene in cervical cancer and precancerous lesions: comparison with cytological and human papillomavirus DNA test findings. Int J Gynecol Cancer. 20:631–637. 2010. View Article : Google Scholar : PubMed/NCBI
42	Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI